Bupivacaine/meloxicam
| Combination of | |
|---|---|
| Bupivacaine | Local anesthetic |
| Meloxicam | Nonsteroidal anti-inflammatory drug (NSAID) |
| Clinical data | |
| Trade names | Zynrelef |
| Other names | HTX-011 |
| License data |
|
| Routes of administration | Intralesional, infiltration |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Bupivacaine/meloxicam, sold under the brand name Zynrelef, is a fixed-dose combination medication used to treat pain in small to medium-sized wounds after surgery.[1][2][4] It contains bupivacaine and meloxicam.[1][2]
The most common side effects of bupivacaine/meloxicam are dizziness, constipation, vomiting, and headache.[1][2]
It was authorized for medical use in the European Union in September 2020,[2] and approved in the United States in May 2021.[1][5]
- ^ a b c d e "Zynrelef- bupivacaine and meloxicam solution". DailyMed. Retrieved 8 January 2022.
- ^ a b c d e "Zynrelef EPAR". European Medicines Agency (EMA). 22 July 2020. Retrieved 6 October 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Zynrelef Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ Blair HA (July 2021). "Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain". Drugs. 81 (10): 1203–1211. doi:10.1007/s40265-021-01551-9. PMID 34228280. S2CID 235744803.
- ^ "Heron Therapeutics Announces U.S. FDA Approval of Zynrelef (HTX-011) for the Management of Postoperative Pain for up to 72 Hours" (Press release). Heron Therapeutics. 13 May 2021. Retrieved 14 May 2021 – via PR Newswire.